Comparative Pharmacology
Head-to-head clinical analysis: SYNERA versus XYLOCAINE 5 W GLUCOSE 7 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SYNERA versus XYLOCAINE 5 W GLUCOSE 7 5.
SYNERA vs XYLOCAINE 5% W/ GLUCOSE 7.5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is an amide-type local anesthetic that stabilizes neuronal membranes by inhibiting sodium ion influx, thereby blocking nerve impulse initiation and conduction. Tetracaine is an ester-type local anesthetic that similarly inhibits sodium channels. The combination provides local dermal anesthesia.
Lidocaine is an amide-type local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion channels, thereby blocking the initiation and conduction of nerve impulses.
Apply 1 patch (70 mg lidocaine and 70 mg tetracaine) to intact skin over the intended venipuncture site or superficial dermatologic procedure site 20-30 minutes prior to procedure; maximum 1 patch per procedure.
Adult: 5-25 mL (250-1250 mg lidocaine) of 5% lidocaine with glucose 7.5% solution, administered by caudal or lumbar epidural injection, single dose. Max total dose: 1250 mg.
None Documented
None Documented
Lidocaine: 1.5–2 hours; prilocaine: 1–1.5 hours. Terminal half-life similar for both. Note: prolonged in hepatic impairment or neonates.
1.5-2 hours (terminal); prolonged in heart failure, hepatic disease, or elderly; neonates 3-6 hours due to immature hepatic function.
Renal excretion of lidocaine and prilocaine metabolites: lidocaine <10% unchanged, prilocaine negligible unchanged. Metabolites primarily renal.
Hepatic metabolism (90% N-dealkylation by CYP1A2/CYP3A4 to monoethylglycinexylidide and glycinexylidide); renal excretion of metabolites and parent drug (<10% unchanged); <1% biliary/fecal.
Category C
Category C
Local Anesthetic
Local Anesthetic